Search research articles
Contact Us
Filters
Showing results (11-20 of 130) with videos related to
Page
of 13
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 28, 2016
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer
Martin Sattler, Ravi Salgia
Haematologica
|
November 6, 2012
A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3
Ellen Weisberg, Martin Sattler
Cancers
|
May 13, 2026
Diagnostic Challenges in Pleural Mesothelioma
Moshe Lapidot, Martin Sattler
Cell Reports. Medicine
|
February 28, 2025
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer
Martin Sattler, Ravi Salgia
Seminars in Hematology
|
June 5, 2003
Molecular mechanisms of transformation by the BCR-ABL oncogene
Martin Sattler, James D Griffin
Journal of the National Cancer Institute
|
May 2, 2007
Chronic myelogenous leukemia progenitors display a genetically unstable personality
Margret S Rodrigues, Martin Sattler
Cancer Cell
|
November 3, 2009
JAK2 gets histone H3 rolling
Martin Sattler, James D Griffin
Methods in Molecular Medicine
|
April 25, 2003
Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases
Martin Sattler, Elizabeth Quackenbush, Ravi Salgia
Thescientificworldjournal
|
October 7, 2008
EGFR-targeted therapeutics: focus on SCCHN and NSCLC
Martin Sattler, Oyewale Abidoye, Ravi Salgia
Cancer Treatment and Research
|
May 29, 2004
Therapeutic targeting of the receptor tyrosine kinase Met
Martin Sattler, Patrick C Ma, Ravi Salgia
Page
of 13
Search research articles
Search
Showing results (11-20 of 130) with videos related to
Sort By:
Page
of 13
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 28, 2016
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer
Martin Sattler, Ravi Salgia
Haematologica
|
November 6, 2012
A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3
Ellen Weisberg, Martin Sattler
Cancers
|
May 13, 2026
Diagnostic Challenges in Pleural Mesothelioma
Moshe Lapidot, Martin Sattler
Cell Reports. Medicine
|
February 28, 2025
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer
Martin Sattler, Ravi Salgia
Seminars in Hematology
|
June 5, 2003
Molecular mechanisms of transformation by the BCR-ABL oncogene
Martin Sattler, James D Griffin
Journal of the National Cancer Institute
|
May 2, 2007
Chronic myelogenous leukemia progenitors display a genetically unstable personality
Margret S Rodrigues, Martin Sattler
Cancer Cell
|
November 3, 2009
JAK2 gets histone H3 rolling
Martin Sattler, James D Griffin
Methods in Molecular Medicine
|
April 25, 2003
Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases
Martin Sattler, Elizabeth Quackenbush, Ravi Salgia
Thescientificworldjournal
|
October 7, 2008
EGFR-targeted therapeutics: focus on SCCHN and NSCLC
Martin Sattler, Oyewale Abidoye, Ravi Salgia
Cancer Treatment and Research
|
May 29, 2004
Therapeutic targeting of the receptor tyrosine kinase Met
Martin Sattler, Patrick C Ma, Ravi Salgia
Page
of 13